Choroideremia is a condition characterized by progressive vision loss that mainly affects males. The first symptom of this condition is usually an impairment of night vision (night blindness), which can occur in early childhood. A progressive narrowing of the field of vision (tunnel vision) follows, as well as a decrease in the ability to see details (visual acuity). These vision problems are due to an ongoing loss of cells (atrophy) in the specialized light-sensitive tissue that lines the back of the eye (retina) and a nearby network of blood vessels (the choroid). The vision impairment in choroideremia worsens over time, but the progression varies among affected individuals. However, all individuals with this condition will develop blindness, most commonly in late adulthood.
Mutations in the CHM gene cause choroideremia. The CHM gene provides instructions for producing the Rab escort protein-1 (REP-1). As an escort protein, REP-1 attaches to molecules called Rab proteins within the cell and directs them to the membranes of various cell compartments (organelles). Rab proteins are involved in the movement of proteins and organelles within cells (intracellular trafficking). Mutations in the CHM gene lead to an absence of REP-1 protein or the production of a REP-1 protein that cannot carry out its protein escort function. This lack of functional REP-1 prevents Rab proteins from reaching and attaching (binding) to the organelle membranes. Without the aid of Rab proteins in intracellular trafficking, cells die prematurely.
The prevalence of choroideremia is estimated to be 1 in 50,000 to 100,000 people. However, it is likely that this condition is underdiagnosed because of its similarities to other eye disorders. Choroideremia is thought to account for approximately 4 percent of all blindness.
Choroideremia is inherited in an X-linked recessive pattern. The CHM gene is located on the X chromosome, which is one of the two sex chromosomes. In males (who have only one X chromosome), one altered copy of the gene in each cell is sufficient to cause the condition. In females (who have two X chromosomes), a mutation must be present in both copies of the gene to cause the disorder. Males are affected by X-linked recessive disorders much more frequently than females. A characteristic of X-linked inheritance is that fathers cannot pass X-linked traits to their sons.
Jasleen Jolly practices in Oxford, United Kingdom. Jolly is rated as an Elite expert by MediFind in the treatment of Choroideremia. She is also highly rated in 7 other conditions, according to our data. Her top areas of expertise are Choroideremia, Late-Onset Retinal Degeneration, Retinitis Pigmentosa, Retinopathy Pigmentary Mental Retardation, and Cataract Removal.
Tomas Aleman is an Ophthalmologist in Philadelphia, Pennsylvania. Aleman has been practicing medicine for over 35 years and is rated as an Elite expert by MediFind in the treatment of Choroideremia. He is also highly rated in 18 other conditions, according to our data. His top areas of expertise are Choroideremia, Leber Congenital Amaurosis, Retinitis Pigmentosa, and Late-Onset Retinal Degeneration. Aleman is currently accepting new patients.
Mariya Moosajee practices in London, United Kingdom. Moosajee is rated as an Elite expert by MediFind in the treatment of Choroideremia. She is also highly rated in 24 other conditions, according to our data. Her top areas of expertise are Choroideremia, Microphthalmia, Usher Syndrome, Coloboma, and Cataract Removal.
Summary: The My Retina Tracker® Registry is sponsored by the Foundation Fighting Blindness and is for people affected by one of the rare inherited retinal degenerative diseases studied by the Foundation. It is a patient-initiated registry accessible via a secure on-line portal at www.MyRetinaTracker.org. Affected individuals who register are guided to create a profile that captures their perspective on the...
Summary: The objective of the study is to evaluate the long-term safety and efficacy of a sub-retinal injection of BIIB111 in participants with Choroideremia (CHM) who have been previously treated with BIIB111 and who have exited an antecedent study; these treated participants will be compared with untreated control participants who have exited the STAR (NCT03496012) study and BIIB112 in participants with ...
Published Date: July 01, 2013Published By: National Institutes of Health